Product Information
ABILIFY MAINTENA ER 300 MG SYR is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2140.3055 per EA under NDC 59148004580. Its NADAC has been published 527 times since Jul 20, 2016.
FDA first approved this application on Feb 28, 2013.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148004580
Classification
Brand
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971FDA Approved
2/28/2013
On Market Since
10/8/2014
Price Statistics
The NADAC for ABILIFY MAINTENA ER 300 MG SYR has been published 527 times since Jul 20, 2016, and over the history we have for it it has risen 65.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2140.3055 per EA |
|---|---|
| All-time high | $2142.7480 (May 13, 2026) |
| All-time low | $1289.9827 (Jul 20, 2016) |
| 52-week high | $2142.7480 |
| 52-week low | $2080.0578 |
| Median price | $1714.3857 |
| Average price | $1750.1271 |
| Largest weekly change | +6.9% (Jan 26, 2022) |
| Weeks tracked | 527 |
| Tracking since | Jul 20, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 300 MG SYR?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 300 MG SYR, manufactured by Otsuka America Pharmaceutical Inc., is $2140.3055 per EA (NDC 59148004580), effective Aug 19, 2026.
How has the price of ABILIFY MAINTENA ER 300 MG SYR changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 300 MG SYR has risen 65.9%. It has been tracked across 527 weekly CMS publications since Jul 20, 2016.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 300 MG SYR?
Since Jul 20, 2016, the NADAC for ABILIFY MAINTENA ER 300 MG SYR has ranged from a low of $1289.9827 (Jul 20, 2016) to a high of $2142.7480 (May 13, 2026), with a median of $1714.3857 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 300 MG SYR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ABILIFY MAINTENA ER 300 MG VL, is $2138.9070 per EA — about 0% below ABILIFY MAINTENA ER 300 MG SYR.
Who manufactures ABILIFY MAINTENA ER 300 MG SYR?
ABILIFY MAINTENA ER 300 MG SYR (NDC 59148004580) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.